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Abstract UDP-N-acetylglucosamine:K(1,6)-D-mannoside L(1,6)-
N- acetylglucosaminyltransferase (GnT-V, Mgat5) functions in
the biosynthesis of N-linked glycans and is transcriptionally
upregulated by oncogene signaling. We report here the cloning
and characterization of a human cDNA encoding a distinct
enzyme with related substrate speci¢city, termed GnT-VB,
which is predicted to have 53% similarity to the original amino
acid sequence of GnT-V(A). Transient expression of GnT-VB
cDNA in COS7 cells yielded signi¢cant increases of activity
toward GnT-VA acceptors, including synthetic saccharides and
N-linked glycopeptides, with some di¡erences in speci¢city. Un-
like GnT-VA, GnT-VB required divalent cation for full activity.
EST databases showed expression of a 6 bp (+) splice isoform
of GnT-VB; when expressed, this enzyme showed signi¢cantly
reduced activity. CHO Lec4 cells, which do not express GnT-
VA or B activity, lack synthesis of the N-linked L(1,6) branch,
and do not bind L-phytohemagglutinin (L-PHA), were trans-
fected with GnT-VB or GnT-VA; both then bound signi¢cant
amounts of L-PHA, demonstrating that both enzymes synthe-
sized N-linked L(1,6) branched glycans in vivo. Real-time poly-
merase chain reaction results showed that GnT-VB mRNA was
highly expressed in brain and testis, with lesser levels in other
tissues, while human GnT-VA showed a more general expres-
sion, but with low levels in brain and no expression in skeletal
muscle.
= 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
Key words: Glycosyltransferase; UDP-N-acetylglucosamine:
K(1,6)-D-mannoside L(1,6)-N-acetylglucosaminyltransferase;
L-Phytohemagglutinin; N-Linked L(1,6) branch
1. Introduction
UDP-N-acetylglucosamine:K-6-D-mannoside L-1,6-N-ace-
tylglucosaminyltransferase V (GnT-V or Mgat5) transfers
N-acetylglucosamine (GlcNAc) to the C-6 position of the L1,6-
linked mannosyl residue in the trimannosyl core structure of
complex-typeN-glycanstogenerateGlcNAc(L1,6)[GlcNAcL1,2]
mannose (Man) (K1,6) [1]. A large amount of information is
available on the expression of the glycans synthesized by
GnT-V because the lectin L-phytohemagglutinin (L-PHA)
binds to the galactosylated product of the GnT-V reaction,
namely, galactose (Gal) L(1,4)GlcNAcL(1,6)ManK(1,6) [1,2].
Consequently, the binding of this lectin to tissue sections, cells
or blots has been used to visualize this product, even after
additional sugars, such as sialic acid, are added. Many studies
have demonstrated the association of increases in L-PHA
binding and GnT-V activity with increases in cell invasiveness,
and in some cases metastatic potential, and with decreased
patient 5-year survival rates [3^7]. The increase in GnT-V
activity and its cell surface products during oncogenesis re-
sults from increased transcription driven by activation of the
ras-ets signaling pathway [8,9]. We report here the cloning
and characterization of an additional member of the GnT-V
family, termed GnT-VB, which shows 41% amino acid iden-
tity and 53% similarity to the original GnT-V sequence, which
will be referred to as GnT-VA.
2. Materials and methods
2.1. Polymerase chain reaction (PCR) cloning of GnT-VB
A BLAST search [10] of the expressed sequence tag (EST) database
identi¢ed a number of cDNAs that showed homology to the pre-
existing human GlcNAcT-V. A full-length open reading frame
(ORF) of an apparently novel GnT was identi¢ed in the Celera data-
base. The cDNA encoding the full-length ORF was obtained by PCR
using brain cDNA (Clontech) and cDNA derived from the SK-N-SH
cell line (ATCC) as templates. The initial cDNA strand was synthe-
sized by SuperScript III transcriptase (Invitrogen) via priming nine
random oligomers and an oligo-dT primer. A 1.9 kb DNA fragment
encoding the N-terminal GnT-VB (1^585) was ampli¢ed by PCR us-
ing primers EcoRI-hVB-F1: 5P-ctcgaattcACGATGGCCCTTCCTG-
CCCTCCTG-3P and hVB-R1986: 5P-CTCTGAGTTGTTGTAGTC-
GACTGT-3P. A 1.3 kb DNA fragment encoding a C-terminal portion
of GnT-VB (305^783) was ampli¢ed using primers hVB-F1262: 5P-
ACGGAGGAGTCCGGGGACGTGTT-3P and NotI-hVB-R2485:
5P-ctcgcggccgcTCACAGACAGCCCTGGCACAAG-3P. These frag-
ments were subcloned into the p3T vector (MoBiTec). To yield a
full-length cDNA, both plasmids were digested with EcoRI and
PmlI. A 1.9 kb DNA fragment encoding an N-terminal portion of
GnT-VB from p3T-VB-Nter was ligated into EcoRI-PmlI-digested
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p3T-VB-Cter. The full-length cDNA was subcloned into pCDNA3.1
(Invitrogen) via EcoRI and NotI restriction sites, named pCD-VB.
Similarly, the GnT-VB 6 bp insert variant was also subcloned into
pCDNA3.1, named pCD-VB(+)6bp, as was the GnT-VA ORF (pCD-
VA).
2.2. Sequence data analysis
An alignment of sequences was constructed by the CLUSTAL W
program, ver. 1.60 [11], and illustrated with MacBoxshade, which was
also used to calculate sequence identity and similarity. Based on the
amino acid sequence alignment, nucleotide alignment was re-con-
structed by the AAtoNuc program, which was a gift from its devel-
oper, Mr. T. Moriya.
2.3. Real-time PCR analysis of GnT-VB transcripts
Marathon ready cDNAs of various human tissues were purchased
from Clontech. Oligonucleotide primers for GnT-VA, GnT-VB, and
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) were designed
with Primer3 software. The primer set for GnT-VA: the forward
primer was 5P-GAGCAGATCCTGGACCTCAG-3P, and the reverse
primer was 5P-GCTGTCATGACTCCAGCGTA-3P. The primer set
for GnT-VB was: 5P-TGTTCTCCCAGCATCCCTAC-3P and 5P-T-
GGCTGCTTCAAACTCCTCT-3P. The primer set for G3PDH was:
5P-CAATGACCCCTTCATTGACC-3P and 5P-GATCTCGCTCCTG-
GAAGATG-3P. Real-time PCR was performed using the iQTM
SYBR Green Supermix (Bio-Rad). The PCR conditions were 95‡C
for 30 s 1 cycle, followed by 40 cycles of 95‡C for 10 s, 65‡C for 30 s;
95‡C for 1 min, and 80 cycles of 55‡C for 1 min for melting curve
analysis. Standard curves for GnT-VA, GnT-VB, and G3PDH
cDNAs were generated by serial dilution of a pCD-VA or pCD-VB
and a p3T vector containing the hG3PDH cDNA.
2.4. PCR-restriction fragment length polymorphism (RFLP) for
detection of 6 bp insert isoform of GnT-VB
To identify the relative abundance of the alternatively spliced iso-
forms of GnT-VB, we performed a PCR-RFLP experiment using
brain and neuroblastoma cDNAs. A 448 bp (or 454 bp for the 6 bp
insert isoform) DNA fragment of GnT-VB (371^517) was ampli¢ed
by primers 5P-CGGCACATGGGACTCTCCTTCAAGAAG-3P and
5P-CCTTGCGCAGCAGCTGCTGAAACTCAGGC-3P. PCR prod-
ucts were digested by BpmI, and subjected to electrophoresis using a
3% agarose gel. The PCR product of the 6 bp insert isoform was
separated into two fragments, 283 and 171 bp, by BpmI digestion.
2.5. GnT-V enzymatic assays toward synthetic oligosaccharide and
N-linked oligosaccharides
The GnT-V activity assays were performed as described [8]. COS7
cells were transiently transfected with pCD-VA, pCD-VB, pCD-
VB(+)6bp or pCDNA3.1 alone by the lipofectamine method (Invitro-
gen). The synthetic tri- and disaccharide acceptors were: GlcNAcL1-
2ManK1-2Glc-O-octyl (Chemica Alta, Canada) and GlcNAcL1-
2ManK1-2-O-octyl (a gift from Dr. O. Hindsgaul), respectively, both
acceptors were used at a concentration of 0.4 mM per reaction. Bian-
tennary and triantennary aminopyridine-labeled (PA) oligosaccharide
acceptors were obtained from glycopeptides digested by thermolysin
(Calbiochem) from bovine ¢brinogen (Sigma) and bovine fetuin (Sig-
ma) respectively as described [12]. Oligosaccharides were released with
2 units of N-glycanase in 0.05 ml K2HPO4 pH 7.5 for 20 h at 37‡C,
and then separated from the peptides using a Sep-Pak C18 cartridge
eluted with 0.1% tri£uoroacetic acid. The glycans were then coupled
to aminopyridine by reductive amination [13]. Acceptor PA-oligosac-
charides were prepared by desialylation (2 N acetic acid, 100‡C for 45
min) and then degalactosylated by 18 h incubation with 1.5 U of
L-galactosidase from Aspergillus oryzae (Sigma), in 0.1 M acetic
acid adjusted to pH 4.5 with triethylamine and analyzed by high per-
formance liquid chromatography (HPLC). The structure of the PA-
oligosaccharide acceptors was con¢rmed by matrix-assisted laser de-
sorption/ionization-time of £ight (MALDI-TOF) mass spectrometry
and by HPLC using a TSK amide column (TosoBiosciences) [14],
comparing the retention times of their £uorescent peaks with those
of authentic bi- and triantennary N-linked standards (V-Labs). For
the glycosyltransferase assays, the PA-asialo-agalacto-biantennary or
triantennary oligosaccharide acceptors were used at a concentration of
15 WM or 10 WM respectively and the reaction products were sepa-
rated by HPLC as described above. Integrations of the £uorescent
peaks separated on HPLC were used to calculate the ratios of product
to unreacted acceptor in each assay. These ratios were then used to
estimate the relative glycosyltransferase activity in each reaction,
where the activity of the cells expressing GnT-VA for each acceptor
was considered to be 100%.
2.6. Flow cytometry and oligosaccharide analysis of Lec4 transfectants
Lec4 cells were transfected with pCD-VB, pCD-VA, or pCDNA3.1,
and cells were selected by 1 mg/ml G418 (Cellgro). After harvesting,
cells were washed two times in phosphate-bu¡ered saline (PBS), then
blocked in PBA (2% bovine serum albumin/0.01% azide/PBS) for 10
min at 4‡C. After blocking, cells were stained with 10 Wg/ml of bio-
tinylated L-PHA (Sigma) in PBA for 30 min at 4‡C, followed by
washing with PBA. Washed cells were stained with phycoerythrin-
conjugated streptavidin (Sigma) for 30 min at 4‡C. Following addi-
tional washing (three times) and ¢xation with 2% formaldehyde in
PBS for 10 min at 4‡C, cells were washed twice with PBA, and ana-
lyzed using a FACSCalibur (BD Biosciences) £ow cytometer. Cell
pellets were sonicated in PBS containing 0.1% Triton X-100 and
then incubated overnight at 37‡C with 1.5% (w/v) of TPCK-treated
trypsin (Pierce). After incubation, the resulting peptide mixture was
boiled for 10 min and dried. N-Linked glycans were then released by
PNGase F, labeled with 2-aminopyridine and analyzed by HPLC as
described above.
3. Results and discussion
We identi¢ed a novel candidate cDNA for human GnT-VB
using a BLAST search of EST databases with the GnT-VA
sequence as a query, which predicted a 2349 bp full-length
ORF. The EST data indicated that the GnT-VB cDNA was
expressed in brain, fetal brain, dorsal root ganglion, spleen,
and tumor cells, including neuroblastoma, liver adenocarcino-
ma, lung large cell carcinoma, skin melanoma, and an epithe-
lioid carcinoma cell line from pancreas. We performed PCR
to isolate a full-length cDNA using brain and neuroblastoma
cDNAs that encoded an ORF with 782 amino acids. The
GnT-VB sequence does not contain a DXD/E motif usually
considered as a potential sugar-nucleotide donor substrate
binding site and/or divalent cation recognition site [15], sim-
ilar to the lack of this motif in the GnT-VA sequence. The
GnT-VB gene was found in the genome sequence (AC016168)
that mapped to chromosome 17q25.3; by contrast, GnT-VA
was located at chromosome 2q21.
Fig. 1 shows an amino acid sequence alignment of GnT-VB
and GnT-VA. The nucleotide sequences showed 49% identity
and 58% similarity, while the amino acid sequences were 41%
identical and 53% similar. During cloning, a splice isoform of
GnT-VB with a 6 bp insert between exon 10 and exon 11
(Fig. 1) was identi¢ed; both isoforms were represented in
the EST database. To identify the relative abundance of the
alternatively spliced isoforms of GnT-VB, we performed a
PCR-RFLP experiment using brain and neuroblastoma
cDNAs as templates. As shown in Fig. 2, neuroblastoma
cDNA was cleaved into two fragments by BpmI, which
cleaved in the 6 bp insert sequence; however, brain cDNA
was not cleaved. These data indicate, therefore, that brain
cDNA contained the isoform of GnT-VB that lacked the
6 bp insert, by contrast to the neuroblastoma cells, which
contained both isoforms.
The expression levels of GnT-VB and GnT-VA transcripts
in human tissues were compared by real-time PCR analysis
under conditions that did not distinguish between the splice
isoforms of GnT-VB. Fig. 3 shows that the GnT-VB tran-
script was highly expressed in brain and testis. Spleen, thy-
mus, and ovary expressed the GnT-VB transcripts at relatively
lower amounts. Skeletal muscle showed low expression, but
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these lower levels were accentuated due to high levels of
G3PDH, which was used for normalization. By contrast,
GnT-VA transcripts were expressed relatively ubiquitously,
except for skeletal muscle, which was almost undetectable,
while brain showed low expression levels.
To characterize enzymatic activity, the coding region for
GnT-VB was transiently transfected into COS7 cells, as was
a similar plasmid encoding GnT-VA, and an empty plasmid
control, since COS7 cells express a low endogenous GnT-V
activity. After 48 h, lysates of these transfectants were assayed
for activity using a synthetic trisaccharide acceptor and con-
ditions commonly used for assay of GnT-VA (Table 1). The
activity of transiently transfected GnT-VA toward this accep-
tor is presented as 100%, and all other activities toward syn-
thetic acceptors are given as relative values to this activity,
since the assay conditions were originally optimized for GnT-
VA. All activities were calculated by subtracting values ob-
tained with mock-transfected cells, typically 6 1%. GnT-VB
showed little activity, but this activity was stimulated signi¢-
cantly in the presence of MnCl2, by contrast to GnT-VA,
which is active in EDTA and shows no stimulation by di-
valent cations. With MnCl2, transiently expressed GnT-VB
displayed about 33% of the GnT-VA activity toward the
trisaccharide acceptor. GnT-VA preferred the trisaccharide
acceptor over the disaccharide lacking the K(1,6)Man residue;
however, GnT-VB displayed no di¡erence in activity toward
the two acceptors. Using PA-labeled asialo-agalacto-bi- and
triantennary acceptors (lacking the L(1,6) branch), GnT-VB
showed 40% and 33% activity, respectively (Table 1), com-
pared to the activity of the GnT-VA enzyme toward each
acceptor, which corresponds well with the relative values be-
tween GnT-VA and GnT-VB observed with the synthetic ac-
ceptors. The splice isoform GnT-VB(+)6bp showed about
14% of the activity of GnT-VA observed toward the trisac-
charide acceptors in the presence of Mn2þ. GnT-VA showed
67% reduced activity toward the synthetic disaccharide,
Fig. 1. Alignment of GnT-V amino acid sequences. Identical residues are boxed (black background with white character for all conserved ami-
no acids, light gray background with black character for three conserved amino acid, and dark gray background with light gray character for
similar amino acids). Putative N-glycosylation sites (GnT-VB) are indicated by a single line and number or a single line and number below the
alignments (GnT-VA). Asterisks indicate the conserved cysteines. Predicted exon^intron junctions are indicated at the top for GnT-VB and at
the bottom for GnT-VA. The 6 bp insert (2 amino acid insert, LQ) is indicated by the arrowhead.
Fig. 2. PCR-RFLP for detection of 6 bp insert isoform. BpmI re-
striction enzyme digestion of PCR fragments from brain and neuro-
blastoma cDNA. Lane 1, neuroblastoma IMR-32 cDNA; lane 2,
SK-N-SH cDNA; lane 3, brain cDNA; lane 4, pCD-VB(+)6bp
plasmid; lane 5, pCD-VB plasmid; and M, 100 bp marker.
Fig. 3. Quantitative analysis of GnT-VA and transcripts in various
human tissues by real-time PCR. The expression levels of GnT-VA
and GnT-VB were each normalized to that of the G3PDH tran-
script. SM, skeletal muscle; SI, small intestine; PBL, peripheral
blood leukocytes.
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GlcNAcL(1,2)Man-octyl compared to the trisaccharide; by
contrast, GnT-VB transferred to the di- and trisaccharide sub-
strates with equal activity, suggesting that GnT-VB may rec-
ognize a more minimal acceptor structure. Interestingly, the
structure, GlcNAcL(1,6)[GlcNAcL(1,2)]Man-O-Ser/Thr, has
been identi¢ed in rabbit brain, and its levels in this tissue
are estimated to be about 15^20% of those of R-GalNAc-O-
Ser/Thr [16]. Since GnT-VB shows high levels of expression in
brain, it is intriguing to speculate that one of the native sub-
strates for GnT-VB is the GlcNAcL(1,2)Man-O-Ser/Thr struc-
ture, and that the product of this reaction may have a phys-
iologically critical function in nerve and brain, as does the
POMGnT1 product.
Lec4 cells lack GnT-V activity and cell surface N-linked
GlcNAcL(1,6) branches that are bound by L-PHA [17]. The
pCD-VB plasmid and pCD-VA plasmid control were used to
transfect Lec4 cells, followed by £ow cytometry analysis using
biotinylated L-PHA that was detected with £uorescently la-
beled streptavidin (Fig. 4). The results showed that both
GnT-VB and GnT-VA expression resulted in similar levels
of L-PHA binding and demonstrated that when expressed in
vivo, GnT-VB is capable of synthesizing L(1,6) branched
N-glycans recognized by L-PHA. The presence of tetraanten-
nary N-linked structures in the transfected cells was con¢rmed
by preparing glycopeptides from both transfectants, releasing
the N-linked structures with N-glycanase, labeling them with
2-aminopyridine, and subjecting them to amino-based HPLC
that separates bi-, tri-, and tetraantennary N-glycans whose
structures were con¢rmed by MALDI-TOF mass spectrome-
try. A £uorescent glycan peak eluting identically to a tetraan-
tennary structure was detected in GnT-VA and B transfec-
tants, but not in mock-transfected cells, demonstrating that
GnT-VB can synthesize in vivo a tetraantennary structure
with a L(1,6) branched mannose (data not shown).
Our results demonstrate, however, that both in vivo and in
vitro GnT-VB is clearly capable of synthesizing N-linked
L(1,6) branched glycans. Because GnT-VB transcript expres-
sion levels are very high in brain relative to GnT-VA, these
results suggest that some of the N-linked L(1,6) branched
structures found in brain may be products of GnT-VB. In
addition, two neuroblastoma cell lines showed high levels of
the transcripts of both splice variants of GnT-VB, and EST
databases revealed that several other tumor-derived cells
showed their expression. Since GnT-VA is transcriptionally
activated by oncogene signaling pathways, it is critical to de-
termine if GnT-VB expression shows similar up-regulation
during oncogenesis, particularly in tumors of neural origin.
4. Note added in proof
Inamori et al. (J. Biol. Chem., in press) have recently re-
ported the sequence corresponding to the +6 bp splice isoform
of GnT-VB, but termed the enzyme encoded by this sequence
‘GnT-IX’. The lack of observable stimulation of enzyme ac-
tivity by Mn2þ using a soluble form of the enzyme toward an
asialo-agalacto biantennary acceptor is likely due to the in-
herently low activity of the +6 bp splice isoform compared to
the 36 bp isoform (Table 1). Human brain appears to express
only the 36 bp isoform (Fig. 2).
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